title: Upfront intraperitoneal chemotherapy for patients with epithelial ovarian cancer: long-term follow-up of a previously published trial.
abstract: OBJECTIVE
  To update previously published work on the long-term survivorship of patients with surgically debulked epithelial ovarian cancer who were treated with intraperitoneal cisplatin-based chemotherapy after initial debulking surgery during the pretaxane era.
  
  
  METHODS
  The records of 15 ovarian cancer patients treated with i.p. cisplatin (CDDP) and either i.v. doxorubicin or i.v. cyclophosphamide from 1985-1993 were reviewed. Data on long-term survivorship, toxicity and ultimate cause of death were updated.
  
  
  RESULTS
  Recurrence-free survival rates for all subjects were 67% at two years, 47% at five years and 40% at 10 years. Five of the 15 (33%) original patients are alive with no evidence of disease (NED) at 180, 183, 205, 228 and 228 months respectively with a median of 205 months since last treatment. Toxicity was present yet posed no long-term threat.
  
  
  CONCLUSIONS
  As presented in the original paper, i.p. chemotherapy can be safely utilized in a community hospital setting. Long-term survival is possible even with suboptimal regimens of chemotherapy as compared with today's standard treatments.
authors: Stamford Hospital, Stamford, USA. Ringers07@yahoo.com
authors: Salvatore A
authors: SA
authors: Del Prete
authors: Matthew C
authors: MC
authors: Ruppel
authors: Jenna M
authors: JM
authors: Hinchey
authors: Christopher J
authors: CJ
authors: Del Prete
authors: Paul L
authors: PL
authors: Weinstein
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D017024:Chemotherapy, Adjuvant / Q000379:methods / Q000401:mortality; D002945:Cisplatin / Q000008:administration & dosage; D002986:Clinical Trials as Topic; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007263:Infusions, Parenteral / Q000379:methods / Q000401:mortality*; D008875:Middle Aged; D009375:Neoplasms, Glandular and Epithelial / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery; D012189:Retrospective Studies; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D004317:Doxorubicin; D003520:Cyclophosphamide; D002945:Cisplatin